Legend Biotech Corporation (LEGN) Earnings History
Net Loss9 years of earnings data (2017–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Legend Biotech Corporation (LEGN) Earnings Overview
As of June 22, 2026, Legend Biotech Corporation (LEGN) reported trailing twelve-month net income of -$250M, reflecting -64.9% year-over-year growth. The company earned $-1.35 per diluted share over the past four quarters, with a net profit margin of -28.8%.
Looking at the long-term picture, LEGN's historical earnings data spans multiple years. The company achieved its highest annual net income of $9M in fiscal 2017.
Legend Biotech Corporation is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including FATE (-$130M net income, -2051.1% margin), CRSP (-$569M net income, -16569.8% margin), BEAM (-$65M net income, -57.2% margin), LEGN has outperformed on profitability metrics. Compare LEGN vs FATE →
LEGN Earnings vs Peers
Earnings metrics vs comparable public companies
LEGN Historical Earnings Data (2017–2025)
9 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$297M | -67.7% | -$137M | $-1.60 | -28.8% | -13.3% |
| 2024 | -$177M | +65.8% | -$303M | $-0.97 | -28.2% | -48.3% |
| 2023 | -$518M | -16.1% | -$439M | $-2.94 | -181.8% | -154.1% |
| 2022 | -$446M | -10.6% | -$456M | $-2.81 | -381.5% | -389.4% |
| 2021 | -$404M | -51.5% | -$392M | $-2.74 | -586.4% | -570.0% |
| 2020 | -$266M | -162.2% | $0 | $-2.57 | -355.2% | 0.0% |
| 2019 | -$102M | -3549.1% | -$133M | $-1.01 | -164.4% | -214.4% |
| 2018 | -$3M | -129.7% | -$2M | $-0.03 | -5.7% | -3.1% |
| 2017 | $9M | - | $14M | $0.07 | 39.7% | 58.4% |
Download Data
Export LEGN earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
9+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
LEGN — Frequently Asked Questions
Quick answers to the most common questions about buying LEGN stock.
What is LEGN earnings per share (EPS)?
LEGN trailing twelve-month (TTM) diluted EPS is $-1.35, reflecting -64.9% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2017 to 2025 is available in the table on this page.
What is Legend Biotech Corporation's net income?
Legend Biotech Corporation (LEGN) trailing twelve-month net income is $-250M as of 2025. Earnings declined -64.9% year-over-year.
Is LEGN profitable?
LEGN is not currently profitable on a TTM basis, reporting a net loss of $-250M. Net margin is -28.8%. Investors should monitor for a return to profitability.
What is LEGN's earnings growth rate?
LEGN compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2017 to 2025.
What are LEGN's profit margins?
Legend Biotech Corporation net profit margin is -28.8%, operating margin is -13.3%, and gross margin is +60.3%. Below-average margins reflect competitive or cost pressures. Return on Equity is -29.1%.
Is LEGN growing earnings?
LEGN earnings are declining — EPS fell -64.9% year-over-year. TTM net income dropped to $-250M. This contrasts with the 5-year CAGR of N/A.
What was LEGN's best earnings year?
Legend Biotech Corporation's highest annual net income on record is $9M, achieved in fiscal year 2017. Earnings history on this page spans 2017 to 2025 and includes all annual and quarterly figures.
What were LEGN's earnings last quarter?
LEGN's most recent reported quarter was Q1 2026. Net income was $-54M with diluted EPS of $-0.30. For a full breakdown of all quarters, see the quarterly earnings table on this page.